Pharmaceutical developers do not often look to softgels as a first choice for drug product formulation, likely due to misconceptions surrounding the development process for softgels and their perceived limitations.
Watch as Kaspar van den Dries, Senior Director of Science and Innovation at Thermo Fisher Scientific, deconstructs common myths surrounding softgels for prescription formulation.